|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Rheology of whey protein O/W emulsions obtained by one and two stage homogenization显示文摘 | DYBOWSKA B E | 2001 | Milchwissenschaft2001，56，11： | 1 |
| 2 | The effects of temperature and homogenization pressure on flow characteristics of whey proteinstabilized O/W emulsions 显示文摘 | Dybowska B E | 2000 | Milchwissenchaft2000，55，4： | 1 |
| 3 | The Effects of Temperature and Homogenization Pressure on Flow Characteristics of Whey Protein Stabilized O/W Emulsions显示文摘 | DYBOWSKA B E | 2000 | Milchwissenchaft2000，55，4： | 1 |
| 4 | Properties of milk protein concentrate stabilized oil-in-water emulsions 显示文摘 | BRYGIDA E Dybowska | 2008 | Journal of Food Engineering2008，88，： | 1 |
| 5 | Optical analysis of glucono-δ-lactone induced soy protein gelation显示文摘 | BE Dybowska Y Fujio | 1998 | Journal of Food Engineering1998，36，： | 1 |
| 6 | Optical Properties of the Pre-gel and Gel State of Soy Proteins Gelled by GDL Under Different pHysical Conditions显示文摘 | BE Dybowska Y Fujio | 1998 | Journal of Food Engineering1998，35，： | 1 |
| 7 | Accumulation dynamics and acute toxicity of silver nanoparticles to Daphnia magna and Lumbriculus variegatus: implications for metal modeling approaches 显示文摘 | Khan FR Paul KB Dybowska AD | 2015 | Environ Sci Technol2015，49，7： | 1 |
| 8 | Elucidation of toxicity pathways in lung epithelial cells induced by silicon dioxide nanoparticles 显示文摘 | OKOTURO- EVANS O DYBOWSKA A VALSAMI- JONES E | 2013 | PLoS One2013，8，72： | 1 |
| 9 | Properties of milk protein concentrate stabilized oil-in-water emulsions显示文摘 | DYBOWSKA B E | 2008 | Journal of Food Engineering2008，，88： | 1 |
| 10 | Arsenic pollu- tion sources 显示文摘 | Garelick H Jones H Dybowska A | 2008 | Reviews of Environmental Contamina- tion and Toxicology2008，197，： | 1 |
| 11 | Fate of isotopically labeled zinc oxide nanoparticles in sediment and effects on two endobenthic species, the clam Scrobic- ularia plana and the ragworm Hediste diversicolor 显示文摘 | Buffet P E Amiard-Triquet C Dybowska A | 2012 | Ec- otoxicology and Environmental Safety2012，84，1： | 1 |
| 12 | Characterisation of carbon nanotubes in the context of toxicity studies显示文摘 | Berhanu D Dybowska A Misra S K Stanley C J Ruenraroengsak P Boccaccini A R Tetley T D Luoma S N Plant J A ValsamiJones E | | 0，，： | 1 |
| 13 | The complexity of nanoparticle dissolution and its importance in nanotoxicological studies显示文摘 | Misra S K Dybowska A Berhanu D | 2012 | Science of the Total Environment2012，438，3： | 1 |
| 14 | Optical properties of the per-gel and gel state of soy proteins gelled by GDL under different physical conditions显示文摘 | Dybowska B E Fujio Y | 1998 | Journal of Food Engineering1998，，35： | 1 |
| 15 | Whey protein - stabilized emulsion properties in relation to thermal modification of the continuous phase 显示文摘 | Dybowska B E | 2011 | Journal of Food Engineering2011，104，： | 1 |
| 16 | The dissolution rates of SiOz nanoparticles as a function of particle size 显示文摘 | Diedrich T Dybowska A Schott J | 2012 | Environmental Science and Technology2012，46，9： | 1 |
| 17 | Properties of milk protein concentrate stabilized oil-in-water emulsions 显示文摘 | DYBOWSKA B E | 2008 | Journal of Food Engineering2008，88，4： | 1 |
| 18 | Factors influencing the failure of interferon-free therapy for chronic hepatitis C:Data from the Polish EpiTer-2 cohort study显示文摘BACKGROUND The introduction of direct-acting antiviral drugs into clinical practice has revolutionized the treatment of chronic hepatitis C,making it highly effective and safe for patients.However,few researchers have analyzed the factors causing therapy failure in some patients.AIM To analyze factors influencing the failure of direct antiviral drugs in the large,multicenter EpiTer-2 cohort in a real-world setting.METHODS The study cohort consisted of patients with chronic hepatitis C treated at 22 Polish centers from 2016-2020.Data collected from the online EpiTer-2 database included the following:hepatitis C virus(HCV)genotype,stage of fibrosis,hematology and liver function parameters,Child-Turcotte-Pugh and Model for End-stage Liver Disease scores,prior antiviral therapy,concomitant diseases,and drugs used in relation to hepatitis B virus(HBV)and/or human immunodeficiency virus(HIV)coinfections.Adverse events observed during the treatment and follow-up period were reported.Both standard and machine learning methods were used for statistical analysis.RESULTS During analysis,12614 patients with chronic hepatitis C were registered,of which 11938(mean age:52 years)had available sustained virologic response(SVR)data[11629(97%)achieved SVR and 309(3%)did not].Most patients(78.1%)were infected with HCV genotype 1b.Liver cirrhosis was diagnosed in 2974 patients,while advanced fibrosis(F3)was diagnosed in 1717 patients.We included patients with features of hepatic failure at baseline[ascites in 142(1.2%)and encephalopathy in 68(0.6%)patients].The most important host factors negatively influencing treatment efficacy were liver cirrhosis,clinical and laboratory features of liver failure,history of hepatocellular carcinoma,and higher body mass index.Among viral factors,genotype 3 and viral load also exerted an influence on treatment efficacy.Classical statistical analysis revealed that treatment ineffectiveness seemed to be influenced by the male sex,which was not confirmed by the multivariate analysis using the machine learning algorithm(random forest).Coinfection with HBV(including patients with on-treatment reactivation of HBV infection)or HIV,extrahepatic manifestations,and renal failure did not significantly affect the treatment efficacy.CONCLUSION In patients with advanced liver disease,individualized therapy(testing for resistance-associated variants and response-guided treatment)should be considered to maximize the chance of achieving SVR. | Ewa Janczewska Mateusz Franciszek Kołek Beata Lorenc Jakub Klapaczyński Magdalena Tudrujek-Zdunek Marek Sitko Włodzimierz Mazur Dorota Zarębska-Michaluk Iwona Buczyńska Dorota Dybowska Agnieszka Czauż-Andrzejuk Hanna Berak RafałKrygier Jerzy Jaroszewicz Jolanta Citko Anna Piekarska Beata Dobracka Łukasz Socha Zbigniew Deroń Łukasz Laurans Jolanta Białkowska-Warzecha Olga Tronina Brygida Adamek Krzysztof Tomasiewicz Krzysztof Simon Malgorzata Pawłowska Waldemar Halota Robert Flisiak | 2021 | World Journal of Gastroenterology2021，27，18： | 0 |
| 19 | Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders显示文摘BACKGROUND It is estimated that 58 million people worldwide are infected with the hepatitis C virus(HCV).Patients with severe psychiatric disorders could not be treated with previously available interferon-based therapies due to their unfavorable side effect profile.This has changed with the introduction of direct-acting antivirals(DAA),although their real-life tolerance and effectiveness in patients with different psychiatric disorders remain to be demonstrated.AIM To evaluate the effectiveness and safety of DAA in patients with various mental illnesses.METHODS This was a retrospective observational study encompassing 14272 patients treated with DAA for chronic hepatitis C in 22 Polish hepatology centers,including 942 individuals diagnosed with a mental disorder(anxiety disorder,bipolar affective disorder,depression,anxiety-depressive disorder,personality disorder,schizophrenia,sleep disorder,substance abuse disorder,and mental illness without a specific diagnosis).The safety and effectiveness of DAA in this group were compared to those in a group without psychiatric illness(n=13330).Antiviral therapy was considered successful if serum ribonucleic acid(RNA)of HCV was undetectable 12 wk after its completion[sustained virologic response(SVR)].Safety data,including the incidence of adverse events(AEs),serious AEs(SAEs),and deaths,and the frequency of treatment modification and discontinuation,were collected during therapy and up to 12 wk after treatment completion.The entire study population was included in the intent-to-treat(ITT)analysis.Per-protocol(PP)analysis concerned patients who underwent HCV RNA evaluation 12 wk after completing treatment.RESULTS Among patients with mental illness,there was a significantly higher percentage of men,treatmentnaive patients,obese,human immunodeficiency virus and hepatitis B virus-coinfected,patients with cirrhosis,and those infected with genotype 3(GT3)while infection with GT1b was more frequent in the population without psychiatric disorders.The cure rate calculated PP was not significantly different in the two groups analyzed,with a SVR of 96.9% and 97.7%,respectively.Although patients with bipolar disorder achieved a significantly lower SVR,the multivariate analysis excluded it as an independent predictor of treatment non-response.Male sex,GT3 infection,cirrhosis,and failure of previous therapy were identified as independent negative predictors.The percentage of patients who completed the planned therapy did not differ between groups with and without mental disorders.In six patients,symptoms of mental illness(depression,schizophrenia)worsened,of which two discontinued treatments for this reason.New episodes of sleep disorders occurred significantly more often in patients with mental disorders.Patients with mental illness were more frequently lost to follow-up(4.2%vs 2.5%).CONCLUSION DAA treatment is safe and effective in HCV-infected patients with mental disorders.No specific psychiatric diagnosis lowered the chance of successful antiviral treatment. | Dorota Dybowska Dorota Zarebska-Michaluk Piotr Rzymski Hanna Berak Beata Lorenc Marek Sitko Michal Dybowski Wlodzimierz Mazur Magdalena Tudrujek-Zdunek Justyna Janocha-Litwin Ewa Janczewska Jakub Klapaczynski Anna Parfieniuk-Kowerda Anna Piekarska Barbara Sobala-Szczygiel Krystyna Dobrowolska Malgorzata Pawlowska Robert Flisiak | 2023 | World Journal of Gastroenterology2023，29，25： | 0 |
| 20 | Best therapy for the easiest to treat hepatitis C virus genotype 1binfected patients显示文摘BACKGROUND The revolution in treatment of patients with chronic hepatitis C virus(HCV)infection dates back to the introduction of direct-acting antivirals(DAAs).The increase in efficacy was most pronounced in patients infected with genotype(GT)1b,as this was the most poorly responsive population to treatment during the interferon era.AIM To identify the most effective interferon-free therapy for GT1b-infected patients and to determine positive and negative predictors of virological response.METHODS This real-world retrospective analysis included patients chronically infected with GT1b HCV whose data were obtained from the multicenter observational EpiTer-2 database.Treatment effectiveness was evaluated for each therapeutic regimen as the percentage of sustained virological responses(SVR).Assessment of the safety was based on the evaluation of the course of therapy,the occurrence of adverse events including serious ones,deaths during treatment and in the post 12-wk follow-up period.RESULTS The studied population consisted of 11385 patients with a mean age of 53±14.8 years and a female predominance(53.4%).The majority of them were treatment-naïve(74.6%)and patients with cirrhosis accounted for 24.3%.Of the DAA regimens used,76.9%were GT-specific with ombitasvir/paritaprevir/ritonavir+dasabuvir±ribavirin being the most used option(32.4%).A total of 10903 patients responded to treatment resulting in a 98.1%in the per-protocol analysis after excluding 273 patients without SVR data.The effectiveness of all regimens exceeded 90%and the highest SVR of 98.9%was achieved in patients treated with a combination of glecaprevir/pibrentasvir.Logistic regression analyses showed that the virologic response was independently associated with female sex[odds ratio(OR)=1.67],absence of decompensated cirrhosis at baseline(OR=2.42)and higher baseline platelets(OR=1.004 per 1000/μL increase),while the presence of human immunodeficiency virus(HIV)coinfection significantly decreased the odds of response(OR=0.39).About 95%-100%of patients completed therapy irrespective of the drug regimen.At least one adverse effect occurred in 10.9%-36.3%and most of them were mild.No treatment related deaths have been reported.CONCLUSION We documented very high effectiveness and a good safety profile across all DAA regimens.Positive predictors of SVR were female sex,absence of decompensated cirrhosis at baseline and higher platelet count while HIV coinfection reduced the effectiveness. | Dorota Zarębska-Michaluk Michal Brzdęk Jerzy Jaroszewicz Magdalena Tudrujek-Zdunek Beata Lorenc Jakub Klapaczyński Włodzimierz Mazur Adam Kazek Marek Sitko Hanna Berak Justyna Janocha-Litwin Dorota Dybowska Łukasz Supronowicz Rafal Krygier Jolanta Citko Anna Piekarska Robert Flisiak | 2022 | World Journal of Gastroenterology2022，28，45： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员